GRAL UPCOMING DEADLINE: SueWallSt Alerts Grail, Inc. Stockholders of Securities Class Action

SueWallSt alerts investors in Grail, Inc. (NASDAQ: GRAL) of a pending securities class action naming senior executives as individual defendants. Class Period: May 13, 2025 through February 19, 2026.

GRAL shares lost $51.32 per share, a 50.55% single-day collapse, after the Company revealed its NHS-Galleri trial failed to achieve its primary endpoint. The Court has set August 4, 2026 as the deadline to apply for lead plaintiff appointment.

Multiple senior officers of Grail are named as individual defendants in this securities class action. Robert P. Ragusa, Chief Executive Officer and Director throughout the Class Period, and Joshua J. Ofman, President throughout the Class Period, each allegedly possessed the power and authority to control the contents of Grail's SEC filings, press releases, and presentations to analysts and institutional investors. The action contends both executives were provided with copies of the Company's public statements prior to issuance and had the ability to prevent their release or cause them to be corrected.

The complaint asserts claims under Section 20(a) of the Securities Exchange Act of 1934, which imposes liability on individuals who act as "controlling persons" of a company that violates federal securities laws. Control person liability does not require proof that the individual personally made a false statement. Rather, it requires that the individual had the power to direct or cause the direction of the company's management and policies.

Ragusa and Ofman allegedly controlled the content of Grail's quarterly earnings releases, conference call scripts, and investor presentations throughout the Class Period Both executives participated directly in earnings calls where they promoted the NHS-Galleri trial's prospects and withheld detailed data from investors Each executive allegedly knew that adverse facts had not been disclosed to the investing public and that positive representations being made were materially false or misleading

The complaint charges that the Individual Defendants' scienter is imputed to Grail under respondeat superior and agency principles

Under Sections 302 and 906 of the Sarbanes-Oxley Act, senior corporate officers who sign SEC certifications bear personal responsibility for the accuracy and completeness of their company's periodic filings. The pleading asserts that the Individual Defendants certified Grail's quarterly reports filed during the Class Period, each of which allegedly contained or incorporated materially misleading statements about the NHS-Galleri trial's likelihood of success.

"Corporate officers have a duty to ensure their companies public statements are accurate and complete. When executives certify SEC filings containing statements about clinical trial prospects, they assume personal responsibility for the accuracy of those representations," stated Joseph E. Levi, Esq.